Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gentamicin collagen sponge is a medical device composed of purified type I bovine collagen impregnated with the aminoglycoside antibiotic gentamicin. It is designed for local application during surgery to prevent and treat wound infections, particularly in high-risk procedures such as cardiac, orthopedic, and gastrointestinal surgeries. The mechanism of action involves the sustained local release of bactericidal concentrations of gentamicin directly at the surgical site, targeting both Gram-negative and Gram-positive bacteria (including Staphylococcus aureus and Pseudomonas aeruginosa), while minimizing systemic exposure and associated toxicity. The collagen matrix gradually degrades via passive diffusion and macrophage activity, ensuring controlled drug delivery. Gentamicin acts by inhibiting bacterial protein synthesis through binding to the 30S ribosomal subunit[1][5]. Clinical studies support its efficacy in reducing surgical site infections (SSIs) after cardiac operations and improving wound healing in various surgical contexts[2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gentamicin collagen sponge.